drugset / Trial / NCT00785694

Recurrence of Bladder Cancer After Transurethral Resection With Hexvix

NCT00785694 ↗

Phase 4 Withdrawn GE Healthcare
RandomizedParallel-groupOpen-labelDiagnostic

Summary

This is a randomised, comparative, multicentre study to determine if the early recurrence rate of intermediate-risk bladder cancer is similar in subjects treated with multiple instillations of mitomycin C after resection conducted under white light cystoscopy (group A) and subjects treated with 1 instillation of mitomycin C after resection conducted under white light and blue light cystoscopy (group B).

Timeline

Start
2008-12
Primary completion
2011-08
Completion
2011-08

Outcome

Outcome not reported

Stopped: “Rejected ethics approval in UK and Holland”

Drugs

EvaluationDrugModalityDoseRoute
Subject hexaminolevulinate Small molecule 50 ml Other